Publications by authors named "A von Kriegsheim"
Article Synopsis
- RAS proteins play essential roles in cell signaling, affecting processes like cell growth, specialization, and death, with KRAS being a notable member commonly mutated in cancers.
- Recent research indicates that not all KRAS mutants are always active, leading to the development of treatments like KRASG12C inhibitors, although resistance remains a challenge.
- The study employs advanced mass-spectrometry proteomics to analyze the interactions of KRAS variants, revealing important insights into KRAS signaling networks and identifying new connections to other signaling pathways, which could aid in creating better-targeted therapies.
Article Synopsis
- The study investigates a form of aniridia and microphthalmia linked to mutations in the MAB21L1 gene, particularly alterations at the Arg51 codon, in patients who do not have typical PAX6 mutations.
- Researchers identified that these mutations appeared de novo in some families and suggested a possible autosomal dominant inheritance pattern.
- Experimental results show that these mutations impact eye development by affecting the function and association of MAB21L1 with various proteins, indicating a potential gain-of-function mechanism rather than a loss-of-function, which is different from typical MAB21L1 mutations leading to milder eye issues.
PRK1 and PRK2 are two closely related AGC-family serine/threonine protein kinases. Here we demonstrate novel roles for them at cilia and in cancer biology. In both instances serum withdrawal leads to increased activating PRK1 and PRK2 phosphorylation (pPRK1/pPRK2) and their depletion results in reduced spheroid growth.
View Article and Find Full Text PDFThe BRAF proto-oncogene serine/threonine-protein kinase, known as BRAF, belongs to the RAF kinase family. It regulates the MAPK/ERK signalling pathway affecting several cellular processes such as growth, survival, differentiation, and cellular transformation. BRAF is mutated in ~8% of all human cancers with the V600E mutation constituting ~90% of mutations.
View Article and Find Full Text PDFPhotosensitizers (PS) are ideally devoid of any activity in the absence of photoactivation, and rely on molecular oxygen for the formation of singlet oxygen ((1)O2) to produce cellular damage. Off-targets and tumor hypoxia therefore represent obstacles for the use of PS for cancer photodynamic therapy. Herein, we describe the characterization of OR141, a benzophenazine compound identified through a phenotypic screening for its capacity to be strictly activated by light and to kill a large variety of tumor cells under both normoxia and hypoxia.
View Article and Find Full Text PDF